{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T02:28:23Z","timestamp":1787538503231,"version":"build-2736575974"},"reference-count":19,"publisher":"Wiley","issue":"14","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2023,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>The development of highly effective <jats:italic>BRAF<\/jats:italic>\u2010targeted therapy and immune checkpoint inhibition for patients with advanced metastatic melanoma has transformed the treatment of this disease. More recently, these advances have moved into the resected, high\u2010risk stage II and III settings. For patients with resected, <jats:italic>BRAF<\/jats:italic>\u2010mutant stage III melanoma, there are no head\u2010to\u2010head data to support the use of <jats:italic>BRAF<\/jats:italic>\u2010targeted therapy (specifically the combination of dabrafenib and trametinib) with either single\u2010agent nivolumab or pembrolizumab. Because the relapse\u2010free and distant metastasis\u2013free survivals are similar in a cross\u2010trial comparison, it is not clear what the best option for these patients is. In this piece, the authors argue on behalf of and against both approaches.<\/jats:p><\/jats:sec><jats:sec><jats:title>Plain Language Summary<\/jats:title><jats:p>\n<jats:list list-type=\"bullet\">\n<jats:list-item><jats:p>Two types of therapy exist for patients diagnosed with melanoma who have completed surgery and remain at high risk for tumor recurrence: (1) drugs that target the <jats:italic>BRAF<\/jats:italic> mutation (found in \u223c50% of patients) and (2) immunotherapy.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>There are no data showing that either approach is better than the other, so the choice of which therapy is best for an individual patient can be challenging.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>In this article, we make arguments for and against each option.<\/jats:p><\/jats:list-item>\n<\/jats:list>\n<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.34806","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T04:34:40Z","timestamp":1684125280000},"page":"2117-2121","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The case for adjuvant <i>BRAF<\/i>\u2010targeted therapy versus adjuvant anti\u2013PD\u20101 therapy for patients with resected, high\u2010risk melanoma"],"prefix":"10.1002","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-8015","authenticated-orcid":false,"given":"Meghan J.","family":"Mooradian","sequence":"first","affiliation":[{"name":"Division of Medical Oncology Massachusetts General Hospital  Boston Massachusetts USA"},{"name":"Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-6645","authenticated-orcid":false,"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology Massachusetts General Hospital  Boston Massachusetts USA"},{"name":"Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(22)00562\u20101"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802357"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709030"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708539"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211437"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010020\u201001188\u20103"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010022\u201001851\u2010x"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586\u2010022\u201005368\u20108"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010018\u20100198\u20100"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010018\u20100197\u20101"},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9605"},{"key":"e_1_2_4_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01763"},{"key":"e_1_2_4_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.9345"},{"key":"e_1_2_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.05.005"},{"key":"e_1_2_4_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0051"},{"key":"e_1_2_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(20)30062\u20100"},{"key":"e_1_2_4_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201017\u20102386"},{"key":"e_1_2_4_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00533"},{"key":"e_1_2_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(20)30417\u20107"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.34806","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T15:23:48Z","timestamp":1760282628000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.34806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":19,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,7,15]]}},"alternative-id":["10.1002\/cncr.34806"],"URL":"https:\/\/doi.org\/10.1002\/cncr.34806","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"assertion":[{"value":"2023-01-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}